ST2-104 decreases the Aβ_25-35-mediated increase in intracellular Ca²⁺. حسب Yingshi Ji (9013004)

Human cerebral organoids treated with VPA show a decreased size, impaired neurogenesis, and induction of senescence in NE cells. حسب Muriel Rhinn (406515)

Knockdown of MRN complex decreases HBV cccDNA level. حسب Kaitao Zhao (3617825)

Knockdown of MRN complex decreases HBV cccDNA level. حسب Kaitao Zhao (3617825)

Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. حسب Daisuke Sugahara (2047696)

TG6-44 treatment leads to decrease in A/X31-induced cell death in THP-1 cells. حسب Juan A. De La Cruz (11154187)

cIN accumulate in the ventrolateral cortex of <i>Emx1</i>-cKO mice. حسب Sathish Venkataramanappa (10331993)

HSF2 regulates ORF50 expression in an RTA independent manner. حسب Lorenza Cutrone (21144285)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes حسب Yun Wu (150224)

الموضوعات:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes حسب Yun Wu (150224)

الموضوعات:

NRX-1 localization to cholinergic axons is decreased in <i>unc-104</i> mutants and colocalizes with UNC-104 in cholinergic axon terminals. حسب Devyn Oliver (12015660)

Partial correlation of <i>ε</i>_max (left column) and IC₅₀ (right column) estimates at 10 days and 20 days (first and second bar of each color, respectively) o... حسب Hope Murphy (8843516)

Ear stimulation targets used of taVNS or staVNS. حسب Duyan Geng (12072181)

الموضوعات:

Fig 4 - حسب Duyan Geng (12072181)

الموضوعات: